Routine hematologic clinical tests as prognostic markers in patients with acute coronary syndromes.
Prognostic markers are needed to identify patients with acute coronary syndrome (ACS) who are at high risk for adverse events. Although the search for new biomarkers is quite active, prognostic information is available from routine hematologic tests, such as the complete blood count. For example, elevated white blood cell counts during ACS are associated with increased risk of mortality, heart failure, shock, and left ventricular dysfunction. Anemia is associated with increased risk of mortality, whereas elevated platelet counts predict poorer clinical and angiographic outcomes. In this review, we summarize the literature regarding the use of clinical hematology tests including white blood cell count, hemoglobin and hematocrit values, and platelet count as prognostic markers in patients with ACS, and we describe potential mechanisms to explain these associations.
Turner
Samuel J
SJ
Department of Internal Medicine/Cardiology, Wake Forest University Health Sciences, Winston-Salem, NC 27157-1045, USA.
Ketch
Terry R
TR
Gandhi
Sanjay K
SK
Sane
David C
DC
D054058:Acute Coronary Syndrome / Q000097:blood / Q000175:diagnosis*; D015415:Biomarkers / Q000097:blood; D006400:Hematocrit; D006454:Hemoglobins; D006801:Humans; D007962:Leukocytes; D010976:Platelet Count; D011237:Predictive Value of Tests; D011379:Prognosis; D012307:Risk Factors
D015415:Biomarkers; D006454:Hemoglobins